LONDON — The United Kingdom has signed a four-year contract with Bavarian Nordic for its mpox and smallpox vaccine, securing scheduled deliveries of the MVA-BN vaccine through the UK Health Security Agency (UKHSA) as part of the country's long-term preparedness against infectious disease threats, according to Reuters and a company announcement on 2 November 2026.
Bavarian Nordic will supply MVA-BN through scheduled deliveries, with optional flexibility provisions included, Reuters reported. The contract value, dose numbers, start date, and expiry date were not disclosed.
Illustration: Vaccine vials stored in a laboratory cold storage facility. This is an illustration, not a real photograph of the vaccine or any actual storage site.
What Happened
On 2 November 2026, Bavarian Nordic announced that it had been awarded the contract by the UK government through UKHSA, according to the company's announcement carried by GlobeNewswire from Copenhagen. The vaccine at the centre of the deal is MVA-BN, described by the company as a non-replicating vaccine indicated for the prevention of mpox and smallpox, supporting long-term preparedness.
Reuters reported the same day that Bavarian Nordic had received a four-year contract from the British government for its mpox and smallpox vaccine, under which it will supply MVA-BN through scheduled deliveries. According to Reuters, the contract includes optional flexibility provisions, although the company did not disclose the contract value.
UKHSA underlined the purpose of the deal in a statement quoted in the reporting. "It is vital to ensure that the UK has the right vaccines available to protect the public from a range of infectious disease threats," UKHSA said. The fuller statement from Sarah Collins, UKHSA Director, Commercial, Vaccines & Countermeasures Delivery, carried in the company announcement, added: "Working with a range of trusted suppliers helps us build a resilient and flexible vaccine supply chain, so we can respond quickly and effectively. This contract is an important part of that ongoing work to keep the public safe."
According to the company, the new contract follows previous UK procurements. Hitesh Sahni, Bavarian Nordic's Senior Vice President for Public Preparedness, said: "We are pleased to continue supporting the UK government's preparedness efforts through this multi-year agreement. Maintaining sustainable vaccine stockpiles and rapid response capabilities are essential to protecting public health and saving lives and we are proud that our vaccine remains an important component of the UK's resilience strategy."
Mpox causes fever and skin lesions and spreads through close physical contact, according to Reuters — which is why governments hold vaccine stockpiles ready in advance rather than waiting for an outbreak to begin.
The announcement did not disclose a delivery timetable or dose numbers for the UK deal. What has been confirmed is the four-year term, the vaccine, the supplier, the route through UKHSA, and the inclusion of flexibility provisions.
Background
To understand the deal, it helps to look at what MVA-BN is. According to Bavarian Nordic, it is the only non-replicating mpox vaccine approved in the United States, Switzerland, Singapore, Mexico (JYNNEOS), Canada (IMVAMUNE), the EU/EEA, and the UK (IMVANEX). The company says it was originally developed as a smallpox vaccine with the US government, including for immunocompromised people, and is indicated for the general population from two years of age at risk of smallpox or mpox.
The UK's recent experience with mpox gives the contract its immediate context. According to UKHSA's epidemiological overview published on GOV.UK on 6 August 2026, up to 31 July 2026 the UK had recorded 119 cases of mpox clade Ib — 82 in England, mostly in London, 24 in Northern Ireland, 7 in Scotland, and 6 in Wales. The first imported clade Ib case in the UK was confirmed in October 2024. From 2023 to 31 July 2026, the UK recorded 1,035 cases of mpox clade IIb, according to the same overview.
Vaccination has been a significant part of the UK response. In England, up to 31 March 2026, 101,210 first doses and 63,915 second doses had been given, according to UKHSA. According to the NHS, the vaccine is usually given in two doses at least 28 days apart, offers around 80% protection after two doses, and is available through sexual health services for groups at higher risk. This article is general health information only, not medical advice, and readers should check NHS and UKHSA guidance for current eligibility details.
Illustration: The London skyline representing public health preparedness. This is an illustration, not a real photograph of London or any health facility.
The global picture has also shaped preparedness planning. The World Health Organization declared mpox a public health emergency of international concern (PHEIC) from July 2022 to May 2023, and again from 14 August 2024 to 4 September 2025, according to WHO material from September 2026. Between 1 January 2022 and 31 July 2026, WHO figures recorded 190,683 confirmed mpox cases and 529 deaths across 145 countries and territories, with around two-thirds of cases in the African Region.
Those figures help explain the shift toward stockpiles: outbreaks that cross borders quickly expose the limits of negotiating separately in the middle of an emergency, and strengthen the case for reserves that can be drawn on at speed. The UK contract and the new global stockpile initiative both sit within that shift — one securing a national supply over several years, the other pooling doses internationally.
Bavarian Nordic's role in the earlier outbreaks is part of that background too. According to Nordic Life Science, reporting on 2 November 2026, the company supplied vaccine to more than 70 countries during the 2022–2024 outbreaks, the vaccine received WHO prequalification for people aged 12 and over in 2024, and its European authorisation was later extended to children aged from two to under twelve.
Why It Matters
The most immediate significance of the UK deal is continuity. A four-year contract, with scheduled deliveries and flexibility provisions, gives UKHSA a predictable supply line instead of a series of short, reactive purchases — and for a health security agency, that predictability is itself a form of protection.
The flexibility provisions reported by Reuters are also worth noting. While their precise terms were not disclosed, an agreement that can adapt if circumstances change is more useful in infectious disease preparedness than a rigid one — and UKHSA's emphasis on a "resilient and flexible vaccine supply chain" points in the same direction.
There is also a broader signal in the timing. According to WHO material from September 2026, a global mpox vaccine stockpile initiative was launched on 27 August 2026, funded by Gavi and coordinated by the International Coordinating Group (ICG), which brings together WHO, UNICEF, Médecins Sans Frontières (MSF), and the International Federation of Red Cross and Red Crescent Societies (IFRC). Nordic Life Science reported on 2 November 2026 that Bavarian Nordic will donate 75,000 MVA-BN doses to that stockpile and supply a further 150,000 doses under contract, with the value undisclosed.
Taken together, the national contract and the global stockpile point to a two-layer preparedness model: countries securing their own multi-year supplies, plus an international reserve for outbreaks wherever they occur.
Illustration: Vaccine distribution boxes being loaded for shipment around the world. This is an illustration, not a real photograph of an actual shipment.
For the public, the practical takeaway is reassurance rather than alarm. The UK is describing long-term preparedness, following previous procurements, with a vaccine that is already approved and already in use — not an unfamiliar threat appearing without warning.
At the same time, the deal is a reminder that preparedness has to be renewed: stockpiles need replenishing, and a multi-year agreement keeps a proven vaccine within the UK's resilience strategy, in Bavarian Nordic's words, so that a rapid response remains possible if it is ever needed.
What Happens Next
In the near term, the contract moves into its delivery phase, with Bavarian Nordic supplying MVA-BN through the scheduled deliveries described in the reporting. No public timetable for individual deliveries has been disclosed, so the next concrete milestones are likely to be official updates from UKHSA or Bavarian Nordic.
On the international side, the global stockpile initiative launched in August 2026 will be one to watch. Coordinated through the ICG, with WHO, UNICEF, MSF, and IFRC involved, and funded by Gavi, it is designed for rapid deployment, and Bavarian Nordic's reported donation and supply add to its initial holdings.
For the UK, the practical questions going forward are whether scheduled deliveries arrive as planned, how the flexibility provisions are used if demand changes, and how the new contract sits alongside the vaccination already delivered in England. UKHSA's epidemiological overviews, published on GOV.UK, remain the best public source for tracking case numbers by nation and region.
Readers who want to know whether they are eligible for vaccination should not rely on a news article for that decision. This article is general health information only, not medical advice; check current NHS and UKHSA guidance or speak to a sexual health service, as eligibility and delivery routes can change.
What is clear from the announcements on 2 November 2026 is the direction of travel: the UK is locking in a multi-year supply of a vaccine it already uses, at the same time as the international community builds a shared reserve. Both moves are about being ready before an emergency, rather than scrambling during one — and that, according to both UKHSA and Bavarian Nordic, is precisely the point.
Sponsored: explore today's featured sponsored offers
FAQ
What vaccine is covered by the UK contract?
The contract covers Bavarian Nordic's MVA-BN vaccine, a non-replicating vaccine indicated for the prevention of mpox and smallpox, according to the company announcement. In the UK it is known as IMVANEX, while in the US it is known as JYNNEOS and in Canada as IMVAMUNE.
How long does the UK contract run?
According to Reuters, the contract runs for four years, with Bavarian Nordic supplying MVA-BN through scheduled deliveries and optional flexibility provisions included. The contract value, dose numbers, start date, and expiry date were not disclosed.
Who is the mpox vaccine for, and how is it given?
According to Bavarian Nordic, MVA-BN is indicated for the general population from two years of age who are at risk of smallpox or mpox. According to the NHS, it is usually given in two doses at least 28 days apart, offers around 80% protection after two doses, and is available through sexual health services for groups at higher risk. Check NHS and UKHSA guidance for current eligibility; this article is general information only, not medical advice.
How many mpox cases has the UK recorded?
According to UKHSA's epidemiological overview of 6 August 2026, up to 31 July 2026 the UK had recorded 119 mpox clade Ib cases — 82 in England, mostly in London, 24 in Northern Ireland, 7 in Scotland, and 6 in Wales — and 1,035 clade IIb cases between 2023 and 31 July 2026. The first imported clade Ib case was confirmed in October 2024.
What is the new global mpox vaccine stockpile?
According to WHO material from September 2026, a global mpox vaccine stockpile initiative was launched on 27 August 2026, funded by Gavi and coordinated by the International Coordinating Group (ICG), which includes WHO, UNICEF, MSF, and IFRC. Nordic Life Science reported on 2 November 2026 that Bavarian Nordic will donate 75,000 MVA-BN doses to the stockpile and supply a further 150,000 doses under contract, with the value undisclosed.
Sources
- Reuters, 2 November 2026
- Bavarian Nordic company announcement via GlobeNewswire, 2 November 2026 (Copenhagen)
- UKHSA epidemiological overview, GOV.UK, 6 August 2026
- NHS mpox vaccine page
- WHO mpox stockpile pages, September 2026
- Nordic Life Science, 2 November 2026
Comments
Post a Comment